Preventive Maintenance Agreement, Qualification Service, and Service Calls for LECO BT2D PEGASUS System with Agilent GC

The Food and Drug Administration's Tobacco Products Laboratory in Atlanta, Georgia is seeking a comprehensive preventive maintenance agreement, qualification service, and service calls for a LECO BT2D PEGASUS System with Agilent Gas Chromatograph, a multi-dimensional gas chromatography instrument used for identifying and quantifying analytes in tobacco products to support FDA regulatory requirements. The procurement includes annual preventive maintenance visits, operational/instrument qualification (OQ/IQ), unlimited service calls with on-site response within three business days, comprehensive warranty coverage for labor and parts, and technical support services. The contract requires services to be performed Monday through Friday between 8:00 a.m. and 4:30 p.m. EST, excluding federal holidays, with all replacement parts being factory new and comprehensive warranty coverage provided. The solicitation will be evaluated based on technical acceptability and lowest price, with vendors required to submit technical capability statements, past performance information, price proposals, and completed representations and certifications. The deadline for quote submission was September 18, 2025 at 12:00 PM ET, with the Q&A period already closed and no further vendor questions being accepted.

This solicitation is not set aside for small businesses and will be awarded under FAR Part 13.106 procedures for commercial items, with the NAICS code 811210 for Electronic and Precision Equipment Repair and Maintenance. The equipment remains the property of LECO Corporation throughout the service contract period, indicating a potential incumbent relationship, though future purchase options may be available at the FDA's discretion. The contract structure includes one base period of 16 months running from January 2026 through January 2027, followed by four one-year option periods that could extend the total contract performance through January 2031. Service delivery is requested to commence between mid-January and February 13, 2026, coordinated with the Contracting Officer's Representative. The place of performance is the FDA's Tobacco Products Laboratory in Atlanta, Georgia, though the solicitation notice lists the performance location as Bethesda, MD, which appears to be an administrative discrepancy given that the detailed contract documents consistently reference the Atlanta facility.